MilliporeSigma News
-
MilliporeSigma Announces Support Of SaudiVax In Becoming First Developer And Manufacturer Of Halal Vaccines And Biotherapeutics In Saudi Arabia
3/18/2022
MilliporeSigma, the U.S. and Canadian Life Science business of Merck KGaA, Darmstadt, Germany, a leading science and technology company, announced that the Life Science business sector will support SaudiVax Ltd., based in the Kingdom of Saudi Arabia, to design a best-in-class, multi-modality manufacturing facility to localize manufacturing of biologics and vaccines for the MENA region.
-
MilliporeSigma To Manufacture Next-Generation Biotherapeutics For Alteogen
3/18/2022
MilliporeSigma announced an agreement with Alteogen, Inc., of South Korea, providing late-stage CDMO services through MilliporeSigma’s BioReliance® End-to-End Solutions. Alteogen selected MilliporeSigma to develop and produce recombinant biologics for the development and clinical evaluation of next-generation therapeutics of monoclonal antibody drugs.
-
MilliporeSigma Announces Organizational Transformation To Strengthen CDMO Offering And Accelerate Future Growth
3/18/2022
MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced several organizational changes and a new operating model to support the long-term growth strategy of the Life Science business sector and to better serve the evolving needs of its global customers.